tradingkey.logo

scPharmaceuticals Inc <SCPH.OQ> expected to post a loss of 38 cents a share - Earnings Preview

ReutersMar 7, 2025 11:31 AM
  • scPharmaceuticals Inc SCPH.OQ SCPH.O is expected to show a rise in quarterly revenue when it reports results on March 11 (estimated) for the period ending December 31 2024

  • The Burlington Massachusetts-based company is expected to report a 98.2% increase in revenue to $12.084 million from $6.1 million a year ago, according to the mean estimate from 6 analysts, based on LSEG data.

  • ​LSEG's mean analyst estimate for scPharmaceuticals Inc is for a loss of 38 cents per share.

  • The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 6 "strong buy" or "buy," no "hold" and no "sell" or "strong sell."

  • The mean earnings estimate of analysts was unchanged in the last three months. ​

  • Wall Street's median 12-month price target for scPharmaceuticals Inc is $17.50​, above​ its last closing price of $3.12. ​​​

Previous quarterly performance (using preferred earnings measure in US dollars). ​

QUARTER ENDING

STARMINESMARTESTIMATE®

LSEG IBES ESTIMATE

ACTUAL

BEAT, MET, MISSED

SURPRISE %

Sep. 30 2024

-0.29

-0.30

-0.75

Missed

-153

Jun. 30 2024

-0.42

-0.41

-0.44

Missed

-6.3

Mar. 31 2024

-0.44

-0.44

-0.36

Beat

17.6​

Dec. 31 2023

-0.52

-0.42

-0.35

Beat

16.4

​​Sep. 30 2023

-0.37

-0.36

-0.41

Missed

-12.4

Jun. 30 2023

-0.37

-0.37

-0.36

Beat

3.3​

Mar. 31 2023

-0.39

-0.36

-0.30

Beat

17.8

Dec. 31 2022

-0.34

-0.39

-0.30

Beat

22.5

This summary was machine generated March 7 at 11:31 GMT. All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)

Disclaimer: The information provided on this website is for educational and informational purposes only and should not be considered financial or investment advice.

Related Articles

KeyAI